Who We Are

Now located in The Colony, Texas, our state-of-the-art, CLIA certified molecular diagnostics laboratory provides a multi-faceted testing portfolio. We focus on pharmacogenomic and cancer genomic testing, as well as infectious disease testing for respiratory, urinary tract, and now COVID-19 pathogens. Our testing methodology combines automation and artificial intelligence to achieve industry leading throughput and accuracy. We work with large corporate employers, institutions, medical providers and facilities to establish broad testing programs to safeguard individuals and businesses. 


Meet Our Leadership Team

Founder & Chief Executive Officer

Frank earned his B.A. in Economics from Southern Methodist University and has led successful toxicology and molecular diagnostic testing laboratories for 8 years, serving vast amounts of clients throughout North America. He is also the founder and CEO of the Gulfstream Companies (Gulfstream Health and Gulfstream Capital). Gulfstream's focus is on opportunistic private debt and equity transactions, and its subsidiaries have deployed in excess of $400m of equity across 75+ investments throughout the United States. Gulfstream has a diverse asset base of passive and active investments focused in healthcare. 

National Accounts Manager

Mark has worked in a variety of industries over his career and has spent the Iast

12 years in and around the healthcare industry. His healthcare assignments have included CPT/ICD coding accuracy improvement, medical record documentation completeness, and medical lien specialty finance. As an award-winning entrepreneur, Mark led one of his companies to be named Virginia's Business of the Year. 

Chief Commercial Officer

Shane brings more than 18 years of sales leadership in the medical and laboratory markets. He has demonstrated the ability to build and lead high-performance sales teams. Before arriving at GenelQ, Shane was Vice President of Sales at Tempus and has held several sales leadership positions at Quest Diagnostics, Applied Proteomics, and Alpha Genomix. 

Chief Administrative Officer

Andre has more than 20 years of professional experience in human resources, including training and development for startup, nonprofit and publicly traded organizations. He oversees all human capital and administrative operations. 

Board of Directors and Advisor

John has extensive experience in CEO and senior executive positions, leading technology-based service companies and creating shareholder value. He has served on private and public company boards as chairman and lead director and chaired audit and compensation committees. 


Meet Our Scientific Team

Chief Scientific Officer

Dr. Adwan graduated with honors from Misericordia University with a B.S. in Biology and Chemistry. He received his Ph.D. in Cell Biology, Stem Cells and Development from the University of Colorado where he also did his postdoctoral fellowship. His research focused on understanding the molecular mechanism underlying salivary gland dysfunction in head and cancer patients. While a graduate student and postdoctoral fellow, Dr. Adwan received numerous grants and awards including the National Research Service Award from the National Institute of Health. In addition, Dr. Adwan is co-author of numerous high-impact, peer reviewed publications. He has been invited to present his work at various scientific meetings including the conference for the Federation of American Societies for Experimental Biology on Lipid Mediated Signaling in Cancer. Before joining our team, Dr. Adwan worked as an assistant professor at An-Najah National University, in their School of Medicine.

Laboratory Director

Dr. Sundin graduated from Old Dominion University where she completed her B.S. in Biology, Ph.D. in Biomedical Sciences, and Postdoctoral Fellowship. She has over 10 years of laboratory experience in cancer biology and clinical molecular diagnostics and is an active member of the Association of Molecular Pathology (AMP). She is widely published and speaks at various symposiums about multidisciplinary facilitation of biomarker testing in cancer patients on behalf of AstraZeneca and Bristol-Myers Squibb. She’s involved with numerous efforts to support the molecular diagnostics field in collaboration with American Medical Technologists (AMT) and the Clinical & Laboratory Standards Institute (CLSI).